ArticleStem cell research & therapy2025
iPSCs derived sEVs ameliorate NK cell senescence by targeting CISH-STAT3.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNatural killer (NK) cells, essential components of the innate immune system, undergo subtype changes with aging that diminish their cytotoxic and tumor surveillance functions. Recent reports indicate that small extracellular vesicles (sEVs) derived from stem cells could ameliorate age-related diseases, while their effects on NK cell senescence remain unexplored.
methodsWe administered induced pluripotent stem cell(iPSC) derived sEVs via tail vein injection for 6 months to naturally aged mouse models. Then we detected a senescent phenotype of splenic NK cells based on a series recognized markers in aged mice. To further investigate the impact of iPSC-sEVs mediated rejuvenation on NK cell function in vivo, purified splenic NK cells from iPSC-sEVs or vehicle-treated mice were co-injected subcutaneously with B16 tumor cells to establish co-inoculation models. In vitro, we used D-gal induced NK92 aged model and conducted transcriptome analysis on the cells. Furthermore, NK92 cells overexpressing CISH were used to explore the mechanism by which iPSC-sEVs improve NK92 cells senescence. Further we conducted a mass spectrometry analysis of the substances in iPSC-sEVs and performed bioinformatics analysis.
resultsiPSC-sEVs treatment partially reversed these immunosenescence phenotypes in aged mice models. In splenic NK and B16 tumor cells co-inoculation models, iPSC-sEVs-NK cells exhibited significantly enhanced cytotoxicity against tumor cells and the ability to recruit T cells. Mechanistic studies suggest that iPSC-sEVs inhibit the upregulation of CISH in senescent NK cells, subsequently activating p-STAT3, which is involved in regulating NK cell senescence and cytotoxicity. Overexpression of CISH significantly suppresses STAT3 phosphorylation and accelerates NK92 cell senescence. Proteomic analysis indicates that iPSC-sEVs modulate the CISH-STAT3 signaling pathway by delivering RNA binding proteins.
conclusionsIn summary, our study shows that iPSC-sEVs effectively rejuvenate senescent NK cells by partially suppressing CISH expression and promoting STAT3 phosphorylation. As a cell-free therapeutic agent, iPSC-sEVs represent a promising strategy for treating cancer in the elderly and other inflammatory senescence-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.